News
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results